OrganOx acquired by Terumo in landmark $1.5bn deal

26 August 2025

The Oxford Science Park warmly congratulates OrganOx Limited on the announcement that it has signed a definitive agreement to be acquired by Terumo Corporation, a global leader in medical technology. The transaction, valued at approximately USD $1.5 billion, marks Terumo’s strategic entry into the organ transplantation-related sector and will see OrganOx become a wholly owned subsidiary.

Founded in 2008 as a spinout from the University of Oxford, OrganOx is a pioneering medical technology company specialising in advanced organ preservation devices for Normothermic Machine Perfusion (NMP). Its flagship device, the metra®, has been used in more than 6,000 liver transplants worldwide and is approved for use in the US, Europe, the UK, Australia and Canada.

A decade at The Oxford Science Park

From 2014 to 2024, OrganOx was based at The Oxford Science Park, where it grew substantially and developed its groundbreaking technology. The company’s time on the Park coincided with a crucial stage in its journey: progressing from innovative research to the global commercialisation of its life-saving device.

Yong Shen, Director of The Oxford Science Park, said:

“Our hearty congratulations go to the OrganOx team on this landmark achievement and we very much look forward to following their continued success as part of Terumo. The Oxford Science Park was OrganOx’s home for over a decade. Their success is a powerful example of how breakthrough science, nurtured in the right environment, can grow into a world-changing solution.”

Expanding opportunities in transplantation

Terumo’s acquisition of OrganOx reflects the growing importance of advanced organ preservation in addressing the global shortage of donor organs. By combining Terumo’s expertise in medical devices with OrganOx’s leadership in organ preservation, the companies aim to expand access to transplantation worldwide, improve post-transplant outcomes, and reduce pressure on healthcare systems.

Hikaru Samejima, CEO of Terumo Corporation, said:

“Organ transplantation represents a last resort for patients with limited treatment options, and addressing the unmet needs in this area carries significant social value. Donated organs are an extremely precious medical resource, and OrganOx’s mission to deliver transplantable organs in optimal condition deeply resonates with our unwavering commitment to patients. Together with OrganOx, we will strive to provide innovative solutions to tackle the diverse challenges surrounding organ transplantation.”

Oern R. Stuge, Executive Chairman of OrganOx, commented:

“OrganOx is a pioneer and leader in organ transplantation technology. Today’s transaction is expected to expand the adoption of our platform by leveraging Terumo’s global infrastructure to benefit more patients around the globe.”

Image credit: Oxford Medical Illustration/OrganOx

Read other news articles

News